The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Drugs for Herpes Labialis (Oral Herpes)-Global Market Insights and Sales Trends 2025
Synopsis
Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
The global Drugs for Herpes Labialis (Oral Herpes) market size is expected to reach US$ 3449.3 million by 2029, growing at a CAGR of 4.9% from 2023 to 2029. The market is mainly driven by the significant applications of Drugs for Herpes Labialis (Oral Herpes) in various end use industries. The expanding demands from the External Use, Oral and Injection,, are propelling Drugs for Herpes Labialis (Oral Herpes) market. Aciclovir, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Valacyclovir segment is estimated at % CAGR for the next seven-year period.
Global Drugs for Herpes Labialis (Oral Herpes) key players include GSK, Novartis, Teva, Mylan, Cadila, etc. Global top five manufacturers hold a share about 55%. North America is the largest market, with a share about 35%, followed by Europe, with a share about 30 percent. In terms of product, Rx Drugs is the largest segment, with a share about 90%. And in terms of application, the largest application is Oral, followed by External Use, and Injection, etc.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Drugs for Herpes Labialis (Oral Herpes), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Drugs for Herpes Labialis (Oral Herpes) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Drugs for Herpes Labialis (Oral Herpes) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Drugs for Herpes Labialis (Oral Herpes) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Drugs for Herpes Labialis (Oral Herpes) covered in this report include GSK, Novartis, Teva, Mylan, Cadila, Apotex, Daewoong Pharmaceutical, Livzon and Luoxin, etc.
The global Drugs for Herpes Labialis (Oral Herpes) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun
Hikma
Haiwang
Carmex
Cipher
Global Drugs for Herpes Labialis (Oral Herpes) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Drugs for Herpes Labialis (Oral Herpes) market, Segment by Type:
Aciclovir
Valacyclovir
Famciclovir
Docosanol
Other
Global Drugs for Herpes Labialis (Oral Herpes) market, by Application
External Use
Oral
Injection
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Drugs for Herpes Labialis (Oral Herpes) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
The global Drugs for Herpes Labialis (Oral Herpes) market size is expected to reach US$ 3449.3 million by 2029, growing at a CAGR of 4.9% from 2023 to 2029. The market is mainly driven by the significant applications of Drugs for Herpes Labialis (Oral Herpes) in various end use industries. The expanding demands from the External Use, Oral and Injection,, are propelling Drugs for Herpes Labialis (Oral Herpes) market. Aciclovir, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Valacyclovir segment is estimated at % CAGR for the next seven-year period.
Global Drugs for Herpes Labialis (Oral Herpes) key players include GSK, Novartis, Teva, Mylan, Cadila, etc. Global top five manufacturers hold a share about 55%. North America is the largest market, with a share about 35%, followed by Europe, with a share about 30 percent. In terms of product, Rx Drugs is the largest segment, with a share about 90%. And in terms of application, the largest application is Oral, followed by External Use, and Injection, etc.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Drugs for Herpes Labialis (Oral Herpes), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Drugs for Herpes Labialis (Oral Herpes) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Drugs for Herpes Labialis (Oral Herpes) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Drugs for Herpes Labialis (Oral Herpes) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Drugs for Herpes Labialis (Oral Herpes) covered in this report include GSK, Novartis, Teva, Mylan, Cadila, Apotex, Daewoong Pharmaceutical, Livzon and Luoxin, etc.
The global Drugs for Herpes Labialis (Oral Herpes) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun
Hikma
Haiwang
Carmex
Cipher
Global Drugs for Herpes Labialis (Oral Herpes) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Drugs for Herpes Labialis (Oral Herpes) market, Segment by Type:
Aciclovir
Valacyclovir
Famciclovir
Docosanol
Other
Global Drugs for Herpes Labialis (Oral Herpes) market, by Application
External Use
Oral
Injection
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Drugs for Herpes Labialis (Oral Herpes) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Drugs for Herpes Labialis (Oral Herpes)
1.1 Drugs for Herpes Labialis (Oral Herpes) Market Overview
1.1.1 Drugs for Herpes Labialis (Oral Herpes) Product Scope
1.1.2 Drugs for Herpes Labialis (Oral Herpes) Market Status and Outlook
1.2 Global Drugs for Herpes Labialis (Oral Herpes) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region (2018-2029)
1.4 Global Drugs for Herpes Labialis (Oral Herpes) Historic Market Size by Region (2018-2023)
1.5 Global Drugs for Herpes Labialis (Oral Herpes) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Drugs for Herpes Labialis (Oral Herpes) Market Size (2018-2029)
1.6.1 North America Drugs for Herpes Labialis (Oral Herpes) Market Size (2018-2029)
1.6.2 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size (2018-2029)
1.6.3 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size (2018-2029)
1.6.4 Latin America Drugs for Herpes Labialis (Oral Herpes) Market Size (2018-2029)
1.6.5 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size (2018-2029)
2 Drugs for Herpes Labialis (Oral Herpes) Market by Type
2.1 Introduction
2.1.1 Aciclovir
2.1.2 Valacyclovir
2.1.3 Famciclovir
2.1.4 Docosanol
2.1.5 Other
2.2 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Historic Market Size by Type (2018-2023)
2.2.2 Global Drugs for Herpes Labialis (Oral Herpes) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Drugs for Herpes Labialis (Oral Herpes) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Drugs for Herpes Labialis (Oral Herpes) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Drugs for Herpes Labialis (Oral Herpes) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Revenue Breakdown by Type (2018-2029)
3 Drugs for Herpes Labialis (Oral Herpes) Market Overview by Application
3.1 Introduction
3.1.1 External Use
3.1.2 Oral
3.1.3 Injection
3.2 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Historic Market Size by Application (2018-2023)
3.2.2 Global Drugs for Herpes Labialis (Oral Herpes) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Drugs for Herpes Labialis (Oral Herpes) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Drugs for Herpes Labialis (Oral Herpes) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Drugs for Herpes Labialis (Oral Herpes) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Revenue Breakdown by Application (2018-2029)
4 Drugs for Herpes Labialis (Oral Herpes) Competition Analysis by Players
4.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Drugs for Herpes Labialis (Oral Herpes) as of 2022)
4.3 Date of Key Players Enter into Drugs for Herpes Labialis (Oral Herpes) Market
4.4 Global Top Players Drugs for Herpes Labialis (Oral Herpes) Headquarters and Area Served
4.5 Key Players Drugs for Herpes Labialis (Oral Herpes) Product Solution and Service
4.6 Competitive Status
4.6.1 Drugs for Herpes Labialis (Oral Herpes) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 GSK
5.1.1 GSK Profile
5.1.2 GSK Main Business
5.1.3 GSK Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions
5.1.4 GSK Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2018-2023)
5.1.5 GSK Recent Developments
5.2 Novartis
5.2.1 Novartis Profile
5.2.2 Novartis Main Business
5.2.3 Novartis Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions
5.2.4 Novartis Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2018-2023)
5.2.5 Novartis Recent Developments
5.3 Teva
5.3.1 Teva Profile
5.3.2 Teva Main Business
5.3.3 Teva Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions
5.3.4 Teva Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2018-2023)
5.3.5 Mylan Recent Developments
5.4 Mylan
5.4.1 Mylan Profile
5.4.2 Mylan Main Business
5.4.3 Mylan Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions
5.4.4 Mylan Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2018-2023)
5.4.5 Mylan Recent Developments
5.5 Cadila
5.5.1 Cadila Profile
5.5.2 Cadila Main Business
5.5.3 Cadila Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions
5.5.4 Cadila Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2018-2023)
5.5.5 Cadila Recent Developments
5.6 Apotex
5.6.1 Apotex Profile
5.6.2 Apotex Main Business
5.6.3 Apotex Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions
5.6.4 Apotex Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2018-2023)
5.6.5 Apotex Recent Developments
5.7 Daewoong Pharmaceutical
5.7.1 Daewoong Pharmaceutical Profile
5.7.2 Daewoong Pharmaceutical Main Business
5.7.3 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions
5.7.4 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2018-2023)
5.7.5 Daewoong Pharmaceutical Recent Developments
5.8 Livzon
5.8.1 Livzon Profile
5.8.2 Livzon Main Business
5.8.3 Livzon Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions
5.8.4 Livzon Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2018-2023)
5.8.5 Livzon Recent Developments
5.9 Luoxin
5.9.1 Luoxin Profile
5.9.2 Luoxin Main Business
5.9.3 Luoxin Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions
5.9.4 Luoxin Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2018-2023)
5.9.5 Luoxin Recent Developments
5.10 Med shine
5.10.1 Med shine Profile
5.10.2 Med shine Main Business
5.10.3 Med shine Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions
5.10.4 Med shine Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2018-2023)
5.10.5 Med shine Recent Developments
5.11 Bayer (Campho Phenique)
5.11.1 Bayer (Campho Phenique) Profile
5.11.2 Bayer (Campho Phenique) Main Business
5.11.3 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions
5.11.4 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2018-2023)
5.11.5 Bayer (Campho Phenique) Recent Developments
5.12 Blistex
5.12.1 Blistex Profile
5.12.2 Blistex Main Business
5.12.3 Blistex Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions
5.12.4 Blistex Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2018-2023)
5.12.5 Blistex Recent Developments
5.13 Kelun
5.13.1 Kelun Profile
5.13.2 Kelun Main Business
5.13.3 Kelun Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions
5.13.4 Kelun Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2018-2023)
5.13.5 Kelun Recent Developments
5.14 Hikma
5.14.1 Hikma Profile
5.14.2 Hikma Main Business
5.14.3 Hikma Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions
5.14.4 Hikma Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2018-2023)
5.14.5 Hikma Recent Developments
5.15 Haiwang
5.15.1 Haiwang Profile
5.15.2 Haiwang Main Business
5.15.3 Haiwang Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions
5.15.4 Haiwang Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2018-2023)
5.15.5 Haiwang Recent Developments
5.16 Carmex
5.16.1 Carmex Profile
5.16.2 Carmex Main Business
5.16.3 Carmex Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions
5.16.4 Carmex Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2018-2023)
5.16.5 Carmex Recent Developments
5.17 Cipher
5.17.1 Cipher Profile
5.17.2 Cipher Main Business
5.17.3 Cipher Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions
5.17.4 Cipher Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2018-2023)
5.17.5 Cipher Recent Developments
6 North America
6.1 North America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Drugs for Herpes Labialis (Oral Herpes) Market Dynamics
11.1 Drugs for Herpes Labialis (Oral Herpes) Industry Trends
11.2 Drugs for Herpes Labialis (Oral Herpes) Market Drivers
11.3 Drugs for Herpes Labialis (Oral Herpes) Market Challenges
11.4 Drugs for Herpes Labialis (Oral Herpes) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
